Monday, October 17, 2011
Sofinnova Ventures was to
announce on Monday this week that it closed an oversubscribed $440 million
fund, its first dedicated entirely to life sciences.
Sofinnova's eighth fund
initially had a $325 million target, with an original hard cap of $400 million,
the firm's James Healy told BioCentury.